文献速递心脑血管急症

性别特异性高敏肌钙蛋白T切点在美国多中心队列中安全性相似但排除效率低于总体切点

Sex-specific high-sensitivity troponin T cut-points have similar safety but lower efficacy than overall cut-points in a multisite U.S. cohort.
PubMed 文献 · Acad Emerg Med · 2024-09-02
一句话结论急诊疑似ACS患者中,性别特异性hs-cTnT切点较总体切点排除率更低(70.6% vs 72.5%),30天心源性死亡或心梗率相似(2.4% vs 2.3%),未改善安全性。

该研究为STOP-CP前瞻性队列的二次分析,纳入美国8个中心急诊科≥21岁、初始心电图无ST段抬高、症状提示ACS的患者。0小时和1小时hs-cTnT均≤99百分位者归入排除组,性别特异性切点为男性22 ng/L、女性14 ng/L,总体切点为19 ng/L。结果显示性别特异性切点排除率低于总体切点(70.6% vs 72.5%,p=0.003),排除组30天心源性死亡或心梗率相似(2.4% vs 2.3%,p=0.79),净重分类改善指数为-2.2%(95%CI -5.1%至0.8%)。结论认为性别特异性切点未改善安全性且导致更少患者被排除。

要点

  • 性别特异性hs-cTnT切点(男22 ng/L、女14 ng/L)的排除率低于总体切点19 ng/L(70.6% vs 72.5%,p=0.003)。
  • 排除组30天心源性死亡或心梗率在性别特异性与总体切点间相似(2.4% vs 2.3%,p=0.79)。
  • 性别特异性切点导致净27例患者被错误重分类至排除组,净重分类改善指数为-2.2%(95%CI -5.1%至0.8%)。
  • 在发生心源性死亡或心梗的患者中,性别特异性切点正确重分类3例女性、错误重分类3例男性。

适用人群与场景

  • 美国8个中心急诊科前瞻性纳入的≥21岁、症状提示ACS且初始心电图无ST段抬高的患者(STOP-CP队列,2017年1月25日至2018年9月6日)。

诊断标准与关键阈值

  • 排除组定义:0小时和1小时hs-cTnT均≤99百分位;性别特异性切点为男性22 ng/L、女性14 ng/L,总体切点为19 ng/L。

研究设计与关键结果

  • 研究类型:STOP-CP前瞻性队列的二次分析;样本量1430例,女性占45.8%(655/1430),平均年龄57.6±12.8岁。
  • 30天心源性死亡或心梗总发生率为12.8%(183/1430)。
  • 排除率:性别特异性切点70.6%(1010/1430) vs 总体切点72.5%(1037/1430),p=0.003。
  • 排除组30天心源性死亡或心梗率:性别特异性2.4%(24/1010) vs 总体2.3%(24/1037),p=0.79。
  • 在发生心源性死亡或心梗的患者中,性别特异性切点正确重分类3例女性、错误重分类3例男性;净27例被错误重分类至排除组。
  • 净重分类改善指数(NRI)为-2.2%(95%CI -5.1%至0.8%)。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与总体切点策略相比,性别特异性hs-cTnT切点导致更少患者被排除,且安全性未改善。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Data comparing the performance of sex-specific to overall (non-sex-specific) high-sensitivity cardiac troponin (hs-cTn) cut-points for diagnosing acute coronary syndrome (ACS) are limited. This study aims to compare the safety and efficacy of sex-specific versus overall 99th percentile high-sensitivity cardiac troponin T (hs-cTnT) cut-points.

METHODS: We conducted a secondary analysis of the STOP-CP cohort, which prospectively enrolled emergency department patients ≥ 21 years old with symptoms suggestive of ACS without ST-elevation on initial electrocardiogram across eight U.S. sites (January 25, 2017-September 6, 2018). Participants with both 0- and 1-h hs-cTnT measures less than or equal to the 99th percentile (sex-specific 22 ng/L for males, 14 ng/L for females; overall 19 ng/L) were classified into the rule-out group. The safety outcome was adjudicated cardiac death or myocardial infarction (MI) at 30 days. Efficacy was defined as the proportion classified to the rule-out group. McNemar's test and a generalized score statistic were used to compare rule-out and 30-day cardiac death or MI rates between strategies. Net reclassification improvement (NRI) index was used to further compare performance.

RESULTS: This analysis included 1430 patients, of whom 45.8% (655/1430) were female; the mean ± SD age was 57.6 ± 12.8 years. At 30 days, cardiac death or MI occurred in 12.8% (183/1430). The rule-out rate was lower using sex-specific versus overall cut-points (70.6% [1010/1430] vs. 72.5% [1037/1430]; p = 0.003). Among rule-out patients, the 30-day cardiac death or MI rates were similar for sex-specific (2.4% [24/1010]) vs. overall (2.3% [24/1037]) strategies (p = 0.79). Among patients with cardiac death or MI, sex-specific versus overall cut-points correctly reclassified three females and incorrectly reclassified three males. The sex-specific strategy resulted in a net of 27 patients being incorrectly reclassified into the rule-in group. This led to an NRI of -2.2% (95% CI -5.1% to 0.8%).

CONCLUSIONS: Sex-specific hs-cTnT cut-points resulted in fewer patients being ruled out without an improvement in safety compared to the overall cut-point strategy.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Montgomery CM, Ashburn NP, Snavely AC, et al. Sex-specific high-sensitivity troponin T cut-points have similar safety but lower efficacy than overall cut-points in a multisite U.S. cohort. Acad Emerg Med. 2024. PMID: 39223791. doi:10.1111/acem.15014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。